Bristol Laboratories is recalling one batch of phenobarbital 60 mg tablets.

The affected batch is:

This is a precautionary measure due to low dissolution test results reported during ongoing stability studies.

Healthcare teams are asked to quarantine all remaining stock and return it to your supplier using your supplier’s approved process.

Patients should continue taking medicines from this batch, as stopping phenobarbital treatment abruptly is likely to cause harm. Patients who experience a change of their condition or symptoms or any adverse reactions should seek medical attention. These should also be reported via the MHRA Yellow Card scheme.